Anondita Medicare IPO timeline and listing gain 2025

What happened and why it matters

Anondita Medicare Limited, a New Delhi-based condom manufacturer, came to the market with a book-building SME IPO in August 2025 and later approved a sizeable rights issue in 2026. The IPO was entirely a fresh issue that raised ₹69.50 crore and listed on the NSE SME platform on September 1, 2025. The stock’s debut was sharp, with the listing price reported at ₹275.50 against an issue price of ₹145, translating into a 90% premium.

The later rights issue approval signals that the company’s board is also planning additional fundraising after the IPO cycle. Alongside corporate actions, the company disclosed a first export purchase order, which is relevant for investors tracking early signs of overseas business traction.

IPO schedule: key dates investors tracked

The IPO subscription window opened on August 22, 2025 and closed on August 26, 2025. The basis of allotment was finalised on August 28, 2025. Refunds were initiated on August 29, 2025, and shares were credited to demat accounts on the same day. The listing date was September 1, 2025 on the NSE SME platform.

These dates matter because they define the exact timeline for application, allotment confirmation, refunds, and the first day of trading. For SME IPOs, market participants also closely watch the period between allotment and listing because liquidity and price discovery can be sharp on debut.

IPO structure: fresh issue, price band, and platform

Anondita Medicare’s IPO was reported as a book-building issue of ₹69.50 crore. The issue was entirely a fresh issue of 47.93 lakh equity shares (4,793,000 shares). The face value per share was ₹10.

The price band for the offer was ₹137 to ₹145 per share, with the issue price also cited at ₹145 per share in the offer details. The IPO was positioned as an SME issue and listed on the NSE SME platform.

Share allocation and market maker portion

The IPO offered 4,793,000 shares in total. One disclosure also provided the category-wise split for the public portion, stating 906,000 shares (18.9026%) for QIB, 681,000 shares (14.2082%) for NII, and 1,584,000 shares (33.0482%) for RII, with the remainder allocated to other buckets.

Separately, the offer details mentioned a market maker reservation of 270,000 equity shares aggregating to ₹3.92 crore. After excluding the market maker reservation portion, the net issue was described as 4,523,000 equity shares aggregating to ₹65.58 crore.

Lot size, minimum application, and retail limits

The article data includes multiple references to lot sizing and retail limits. One line states the IPO lot size was 2,000 shares. Another table lists a lot size of 1,000 shares, with a minimum investment of ₹145,000 and a retail maximum of 2,000 shares or ₹290,000.

In the same set of details, it is stated that investors could apply for a minimum of 1,000 shares, and that retail investors needed to apply for at least two lots, implying 2,000 shares and an investment of ₹290,000 at ₹145 per share. Readers should note these figures as presented in the provided data.

Listing outcome: reported debut at 90% premium

On listing day, September 1, 2025, Anondita Medicare shares were reported to have listed at ₹275.50. This was stated as a 90% premium over the public offer price of ₹145 on the NSE SME platform.

For IPO watchers, this listing outcome is one of the most visible datapoints because it captures immediate secondary market demand. It also sets a reference point for any later corporate actions such as rights issues and for assessing how the market is valuing the company post-IPO.

Business profile: products, capacity, and facility

Anondita Medicare was incorporated in 2024. The company manufactures male condoms and also noted that it has recently manufactured female condoms. Its flagship product brand was cited as “COBRA,” and it produces flavoured male condoms.

The company’s reported production capacity is 562 million condoms annually. Its manufacturing facility is situated in Noida, Uttar Pradesh.

Export order disclosure: first purchase order from South Africa

Anondita Medicare disclosed that it secured its first export purchase order worth approximately ₹43.14 crore. The order was from Supra Healthcare Johannesburg (Pty) Ltd., South Africa, and was linked to the South African Government condom procurement program.

This disclosure is relevant because it is positioned as the company’s first export purchase order, which can help investors track the shift from a domestic footprint to international execution.

Rights issue approval in 2026: amount, structure, and committee

The company’s board approved a rights issue proposal to raise up to ₹109.78 crore (stated as 10,978.20 lakh rupees and also as approximately ₹109.78 crore). The disclosure stated that the decision was taken in a board meeting held on Saturday, August 1, 2026.

As per the proposal, the company will issue fully paid-up equity shares of face value ₹10 to eligible equity shareholders. The record date for determining rights issue eligibility will be decided and notified later.

The board also formed a three-member committee to complete rights issue processes. Anupam Ghosh was named committee chair, with Reshant Ghosh and Lakhinder Singh as members, and the committee was empowered to take necessary issue-related decisions and complete formalities.

Key facts table

Registrar, lead manager, and allotment status steps

Narnolia Financial Services acted as the book-running lead manager, and Maashitla Securities was the registrar of the issue. The provided contact details for the company include: Flat No.704 Namada Block N6 Sec-D Pkt-6, Vasant Kunj, New Delhi-110070, phone 0120-4520 300, email info@anonditamedicare.com, and website www.anonditamedicare.com.

For the registrar, the details provided were: phone 011-45121795, email ipo@maashitla.com, and website www.maashitla.com.

To check the IPO allotment status, the steps listed were: visit the registrar website, go to the IPO allotment status page, select “Anondita Medicare Ltd,” enter PAN number or application number or DP/Client ID, and submit to view the status.

What investors will watch next

From the available information, the next concrete corporate step is the rights issue process, including the company’s later notification of the record date and other final terms. Investors typically track how the rights issue is priced and scheduled, and how the company communicates the use of proceeds, but those details were not provided in the supplied text.

For now, the documented sequence remains clear: a ₹69.50 crore SME IPO in August 2025, a reported 90% premium listing on September 1, 2025, an export order disclosure of ₹43.14 crore, and a board-approved rights issue plan capped at ₹109.78 crore in 2026.